Enzymotec Ltd. (ENZY) Shares Up 3.5%
Enzymotec Ltd. (NASDAQ:ENZY) shot up 3.5% during mid-day trading on Monday . The stock traded as high as $8.03 and last traded at $8.01, with a volume of 52,706 shares. The stock had previously closed at $7.74.
Several research firms recently issued reports on ENZY. Jefferies Group reaffirmed a “hold” rating on shares of Enzymotec in a research note on Sunday, May 22nd. Zacks Investment Research downgraded shares of Enzymotec from a “buy” rating to a “hold” rating in a research report on Friday, July 22nd.
The company has a market capitalization of $181.98 million and a P/E ratio of 42.16. The firm has a 50 day moving average of $8.55 and a 200-day moving average of $8.42.
Enzymotec (NASDAQ:ENZY) last issued its earnings results on Tuesday, August 9th. The company reported $0.04 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.08 by $0.04. The business earned $15 million during the quarter, compared to analysts’ expectations of $14.90 million. The company’s quarterly revenue was down 12.7% on a year-over-year basis. During the same period last year, the firm posted $0.11 earnings per share. On average, analysts forecast that Enzymotec Ltd. will post $0.27 earnings per share for the current fiscal year.
Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company’s technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company’s segments offer a range of products that leverage its lipid-related offerings.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.